Testosterone Injections — How Often Should You Do Them, and What to Expect?
Less frequent testosterone injections buy convenience at the cost of bigger swings in blood levels; more frequent, smaller doses flatten that curve at the cost of extra injections. We show real schedules, real numbers, and what to expect in your body between doses.
Number of studies
3
Safety
Requires caution
Time to effects
A new frequency schedule reaches its target, repeatable concentration profile usually after 3–5 half-lives of the ester used — for cypionate/enanthate, that's roughly 3–5 weeks of regular use. Subjectively assessing whether a given schedule actually flattened well-being swings usually requires observing at least 2–3 full dosing cycles on the new rhythm, not a single injection.
Who it's for
Table of contents
TL;DR
Less frequent testosterone injections buy convenience at the cost of bigger swings in blood levels; more frequent, smaller doses flatten that curve at the cost of extra injections. We show real schedules, real numbers, and what to expect in your body between doses.
- →A deliberate choice of frequency lets you match the schedule to your own sensitivity to mood and energy swings
- →More frequent, smaller doses can limit the swing in estradiol and hematocrit at the same total weekly dose
- →Understanding the peak-trough mechanism helps distinguish a natural "dip" in the dosing cycle from a genuine decline in health
| Type of intervention | Choosing an injection-frequency schedule within already-started injectable TRT |
|---|---|
| Level of evidence | Moderate — pharmacokinetic and observational data, no large RCTs directly comparing frequencies on hard endpoints |
| Target group | Men already approved for injectable TRT, setting or adjusting a dosing schedule with their doctor |
| Key trade-off | Less frequent injections = more convenience, but a larger peak-trough swing in concentrations |
| Clinical practice trend | Growing popularity of more frequent, smaller dosing (weekly or twice weekly) for estradiol and hematocrit stability |
| Status | An element of the treatment plan set individually with a doctor, not a decision made alone |
Understand
Overview
Once a patient has settled on injections as their TRT delivery form — rather than, say, gel, which we cover separately in our comparison of injections versus testosterone gel — a second, equally important question remains: how often should they be done? That question sounds technical, but it has very practical consequences: injection frequency determines how much blood testosterone "swings" between doses, and some men genuinely feel those swings — as cyclical changes in energy, mood, and libido that track the injection calendar.
This entry doesn't repeat the general overview of testosterone delivery forms (injections, gels, patches) found in our entry on TRT delivery forms, or the comparison of injections versus gel. We focus purely on the mechanics of injection frequency itself: what happens to the testosterone concentration curve at different dosing intervals, which dosing schedules are actually used in clinical practice today, why more clinics and patients are shifting toward more frequent, smaller dosing, and what that means day to day — from rotating injection sites to when it makes sense to get a blood test.
The basic trade-off is simple to understand but hard to feel without numbers: the less often you inject, the larger a single dose has to be to keep average testosterone in the therapeutic range for the whole interval — and a larger dose means a higher peak right after the injection and a deeper dip right before the next one. With the esters typically used in Poland (cypionate, enanthate), which have a half-life of roughly 7–8 days, an injection every two weeks can produce a testosterone level in the first days after injection two or three times higher than right before the next dose. A weekly injection, with the same total weekly dose spread out differently, flattens that curve — the peak is lower, the trough shallower, and the swings less subjectively noticeable.
This isn't purely pharmacokinetic theory. Studies on subcutaneous weekly testosterone enanthate injections show that this schedule keeps testosterone within the reference range across the entire seven-day interval between doses, with relatively little variability compared to a standard intramuscular injection every two weeks (Kaminetsky et al., 2015). Clinical practice is also increasingly shifting toward more frequent dosing — not just for steadier well-being, but also to limit the swing in estradiol and hematocrit, both of which rise in proportion to the peak testosterone concentration after an injection — a smaller, more frequent dose gives a lower peak, and so a smaller "spike" in aromatization to estradiol and a smaller stimulus for red blood cell overproduction.
It's worth stating up front, though: there's no single "correct" schedule. Choosing a frequency is always a balance between steady well-being, practicality (fewer injections means fewer chances to make a mistake, forget a dose, or irritate the skin), and individual response, which can vary surprisingly between patients on the exact same schedule. The final schedule is always set jointly with the treating physician, based on blood results and how you feel through a dosing cycle — not decided upfront from theory alone.
Mechanism of action
The source of differences in the concentration profile is how the body releases testosterone from the injection site. Pure testosterone has a half-life of a few dozen minutes — practically unusable for regular dosing. That's why injections use esters (cypionate, enanthate, less commonly propionate or undecanoate) — a testosterone molecule bonded to a fatty acid chain that slows the hormone's release from an intramuscular or subcutaneous oil depot. The longer the ester chain, the slower the release and the longer the effective half-life — and that directly determines how often you need to inject to maintain a stable concentration.
Propionate has a short chain and a half-life of roughly 1–2 days, which in practice forces injections every 2–3 days — rarely used alone in TRT for that reason, though it's sometimes combined with longer esters to reach a therapeutic concentration faster at the start of therapy. Cypionate and enanthate have a similar half-life of roughly 7–8 days, which makes them the most commonly chosen esters in standard TRT — they allow dosing anywhere from once a week to once every two weeks, depending on whether stability or a less frequent intervention is the priority. Testosterone undecanoate has a completely different profile: a very long ester chain gives it a half-life measured in weeks, allowing injections just a few times a year, usually every 10–14 weeks after an initial loading phase — the full rundown of all forms and esters, with their pros and cons, is in our entry on TRT delivery forms.
From the perspective of the concentration-over-time curve, each individual injection creates its own cycle: a rapid rise in concentration over 24–72 hours to a peak, followed by a gradual decline until the next dose. When the interval between doses is long relative to the ester's half-life (e.g., injecting every 2 weeks with an ester that has a 7–8 day half-life), the body spends a significant part of the cycle below the peak concentration, at times approaching the lower edge of the reference range right before the next dose. When the interval is shorter relative to the half-life (e.g., injecting weekly or twice a week), the next dose "stacks" on top of the previous one, which hasn't been fully eliminated yet, which mathematically flattens the swing amplitude and raises the trough value closer to the peak value — this is exactly the mechanism by which more frequent, smaller doses produce a more stable profile at the same total weekly dose.
The same relationship applies to testosterone's metabolites — estradiol (via aromatase) and dihydrotestosterone, and indirectly to bone marrow stimulation for red blood cell production. A higher testosterone peak after a large, infrequent dose means more substrate momentarily available for the aromatase enzyme, translating into a higher peak estradiol than the same total dose split into more frequent injections. Similarly, the risk of excessive hematocrit rise (erythrocytosis) is more strongly linked to high peak testosterone concentrations than to the average concentration across the cycle — a literature review on erythrocytosis following testosterone therapy specifically points to forms with high peaks (infrequent intramuscular injections) as carrying a higher risk of this side effect than forms with a more stable profile (Ohlander et al., 2018).
The ester determines the release rate
The length of the ester chain (propionate, cypionate/enanthate, undecanoate) determines the half-life and the required dosing frequency.
A shorter interval relative to the half-life flattens the curve
When the next dose is given before the previous one is mostly eliminated, the swing amplitude shrinks and the trough value rises.
A higher peak means more substrate for aromatase
A large, infrequent dose gives a momentarily higher testosterone concentration available for conversion to estradiol than the same dose split into more frequent injections.
Peak concentrations stimulate bone marrow more strongly
The risk of excessive hematocrit rise correlates more strongly with the height of the testosterone peak than with the average concentration across the dosing cycle.
Evidence: moderate — based on 3 studies in this database.
Benefits
Common myths
MythMore frequent injections mean a higher total testosterone dose and faster effects.
FactIt's about splitting the same total weekly dose into more, smaller injections, not increasing it. The goal is flattening the concentration curve, not raising the average testosterone level in the body.
MythIf I feel bad near the end of the interval between doses, it means the dose is too low and needs to be increased.
FactA decline in well-being in the last days of the cycle is often a natural effect of the concentration trough at that frequency, not proof that the total dose is too low. A more frequent, and often more effective, fix is shortening the interval between doses at the same total testosterone amount, not increasing it.
MythOnce a dosing schedule is set, it should stay unchanged for the entire course of therapy.
FactInjection frequency is one of the easiest elements of TRT to adjust — switching from every-2-weeks to weekly or twice weekly is a common, simple modification when blood results or well-being suggest it's needed.
Forms & variants
Testosterone Injections — How Often Should You Do Them, and What to Expect? comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Every 1 week (cypionate/enanthate)
The most commonly used default schedule today. Moderate swing amplitude — a clear but not overly deep peak and trough within a single week. A good starting point for most patients.
Best for: Patients looking for a balance between convenience and steady well-being; a typical first choice
Every 10–14 days (cypionate/enanthate)
Less common today than it used to be, but still seen — fewer injections per month at the cost of a more pronounced peak-trough difference than weekly dosing.
Best for: People who tolerate swings well and prioritize a less frequent intervention
Every 2 weeks (cypionate/enanthate)
A classic, historically very popular schedule. Produces the largest swing amplitude among mid-half-life esters — some patients notice a clear drop in energy and mood in the last days before the next dose.
Best for: Less often recommended today as a first choice; sometimes maintained in patients who've tolerated it well for years
Twice a week (micro-dosing)
The same total weekly dose split into two smaller injections. The flattest concentration curve among cypionate/enanthate-based schedules — an increasingly popular trend, especially for those prone to high estradiol or hematocrit.
Best for: Patients sensitive to well-being swings or with a history of high estradiol/hematocrit on less frequent dosing
Every 10–14 weeks (testosterone undecanoate)
An entirely different time category thanks to the ester's very long half-life. After a loading-dose phase at the start of therapy, just a few injections a year. Requires an intramuscular injection in a clinical setting because of the volume and the risk of a rare but serious complication (pulmonary oil microembolism).
Best for: Patients who value maximum infrequency of intervention and accept the need to be dosed at a medical facility
Practice
Frequently asked questions
Both frequencies, at an appropriately chosen dose, can keep average testosterone within the therapeutic range. The difference is in the swing amplitude: weekly dosing gives a shallower peak-trough curve than every two weeks with the same ester, which some patients experience as steadier well-being. People who tolerate swings well and value a less frequent intervention may still knowingly choose the two-week schedule.
It's a colloquial term for the drop in energy, mood, or libido in the last days before the next injection, as testosterone concentration approaches the lowest point of the dosing cycle (the trough). It occurs in some, though not all, patients on injections, and is more pronounced with less frequent dosing. If it's bothersome, it's worth discussing shortening the interval between doses with your doctor — a typical, simple fix for the problem.
No — it's an increasingly popular schedule, especially in more modern clinical practice, precisely because it further flattens the concentration curve compared to once-weekly dosing at the same total weekly dose. The only cost is an extra injection — not a higher total dose or greater overdose risk.
It depends on what the doctor wants to assess. A measurement right before the next dose (the trough value) shows the lowest point of the cycle and helps check whether concentration doesn't drop too low near the end of the interval. A measurement mid-interval gives a value closer to the average across the whole cycle. Testing should be avoided within the first 1–2 days after an injection, since the result will show an artificially inflated peak concentration, not useful for assessing the typical level.
Not necessarily — often it's purely a matter of spreading the same total weekly dose across a different number of injections (e.g., 100 mg once a week switched to 50 mg twice a week). Changing frequency alone without changing the total dose is one of the simplest TRT schedule adjustments and is often the first step when dealing with well-being swings, estradiol, or hematocrit issues.
That's a different question. The injections-versus-gel comparison covers choosing a TRT delivery form in the first place — before you've decided on anything. This entry assumes injections have already been chosen, and answers the next question: how often to do them for the concentration profile that works best for you. The full comparison of forms is in our entry on injections versus testosterone gel.
Dosage & timing
Typical dose
Cypionate/enanthate: most often 50–100 mg weekly, 100–150 mg every 10–14 days, or 25–50 mg twice a week at the same total weekly dose. Undecanoate: 750–1000 mg every 10–14 weeks after a loading-dose phase (a separate schedule — see our entry on delivery forms).
Form
Intramuscular injections (usually the gluteal muscle or thigh) or subcutaneous (abdomen, thigh) — the choice of route and frequency depends on the preparation, patient preference, and tolerance.
There's no single universal frequency — the total weekly dose and how it's split across injections are chosen individually and adjusted based on blood results and reported swings in well-being, not fixed once at the start of therapy with no further review.
Best times to take it
- Pick a fixed day (or days) of the week for injections — the regularity of the interval matters more for concentration stability than the chosen frequency itself
- Rotate injection sites in a fixed pattern (e.g., alternating left/right side, or successive quadrants of the glute or thigh) — this reduces the risk of local tissue hardening from repeated dosing in the same spot
- Plan a blood test to measure testosterone deliberately relative to the injection: a measurement right before the next dose shows the trough value (the cycle's lowest point) and is useful for checking whether concentration doesn't drop below normal near the end of the interval; a measurement mid-interval gives a more averaged value representative of the whole cycle — which to choose is up to the doctor, depending on what they want to assess
- Avoid getting blood drawn within the first 24–48 hours after an injection — that's the peak-concentration window, which doesn't reflect the typical level in the cycle and can lead to a mistaken decision to lower the dose
- Estradiol and hematocrit are worth monitoring on the same rhythm as testosterone, ideally at the same point in the dosing cycle each time, so results between checks are comparable
Safety
Side effects & contraindications
Possible side effects
With less frequent injections (every 2–3 weeks): possible drop in energy, mood, or libido in the last days before the next dose (so-called "troughing")
With more frequent dosing: more chances for local pain, redness, or hardening at the injection site — simply because there are more injections in the same period
Possible worsening of acne or fluid retention around the peak days after a dose, especially with larger, less frequent doses
Rarely: an injection-site reaction (redness, itching) lasting more than a few days — worth reporting to a doctor
Contraindications
History of prostate or breast cancer
Untreated, severe heart failure
Undetermined cause of elevated PSA
Uncontrolled polycythemia or significantly elevated hematocrit — may require a change in frequency or form, not just dose
Planning to father a child in the near term without additional consultation
Interactions
Anticoagulants — testosterone can enhance their effect regardless of the dosing schedule
Insulin and antidiabetic medications — dose adjustment may be needed when injection frequency changes and average testosterone concentration shifts as a result
Corticosteroids — possible increased fluid retention, more noticeable around peak days after a dose
Is it worth taking?
Who it's for
- Men just starting injectable TRT, setting their first dosing schedule with a doctor
- Patients on TRT experiencing cyclical swings in energy, mood, or libido that track the timing of their next dose, considering a frequency change
- People with elevated estradiol or hematocrit on their current schedule, looking for arguments to discuss more frequent, smaller dosing
- Patients who want to deliberately plan the timing of a blood test relative to an injection so the results are reliable
Not for
- History of prostate or breast cancer
- Untreated, severe heart failure
- Undetermined cause of elevated PSA
- Uncontrolled polycythemia or significantly elevated hematocrit — may require a change in frequency or form, not just dose
- Planning to father a child in the near term without additional consultation
Evidence
Worth knowing
Testosterone without an ester has a half-life of a few dozen minutes — it's the esters (cypionate, enanthate, undecanoate) that allow dosing less often than daily.
Cypionate and enanthate have a similar half-life of roughly 7–8 days, allowing dosing anywhere from once a week to once every 2 weeks depending on the priority — stability or a less frequent intervention.
Testosterone undecanoate, thanks to a much longer half-life, is dosed only every 10–14 weeks after a loading-dose phase.
The height of the peak testosterone concentration after an injection correlates with the size of the estradiol rise and the risk of elevated hematocrit more strongly than the average concentration across the cycle.
Studies
Weekly subcutaneous dosing of testosterone enanthate achieved a stable, in-range testosterone concentration across the entire seven-day interval between injections, with lower variability than standard intramuscular injection every two weeks.
Kaminetsky J, Jaffe JS, Swerdloff RS, Sexual Medicine, 2015
Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study
Moderate evidenceKaminetsky J, Jaffe JS, Swerdloff RS · Sexual Medicine · 2015
A phase II study comparing weekly subcutaneous doses of testosterone enanthate (50 or 100 mg) with a standard 200 mg intramuscular injection every two weeks. Weekly subcutaneous dosing kept testosterone within the reference range across the entire seven-day interval, with less variability than the two-week schedule.
View studyPharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial
Strong evidenceWang C, Harnett M, Dobs AS, Swerdloff RS · Journal of Andrology · 2010
An 84-week phase III trial of testosterone undecanoate given every 10 weeks after loading doses. Steady state was reached after the third injection; at that point, 94% of men maintained an average testosterone concentration within normal range across the third dosing interval, with small peak-trough swings characteristic of this ester's very long half-life.
View studyErythrocytosis Following Testosterone Therapy
Moderate evidenceOhlander SJ, Varghese B, Pastuszak AW · Sexual Medicine Reviews · 2018
A literature review on erythrocytosis (excessive hematocrit rise) following testosterone therapy, pointing to delivery forms and dosing schedules that produce high peak testosterone concentrations as carrying higher risk of this side effect than profiles with a more stable, flattened concentration course.
View studySources & bibliography
- Kaminetsky, Jaffe, Swerdloff 2015 — Sexual Medicine
- Wang et al. 2010 — Journal of Andrology
- Ohlander, Varghese, Pastuszak 2018 — Sexual Medicine Reviews
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Related entries
4.4TRT — Administration Forms: Injections, Gels, and Patches
Injections, transdermal gels, and patches — the three main forms of testosterone replacement therapy differ in blood-concentration profile, ease of use, and the risk of transferring the hormone to other people.
4.6Injections or Gel? Which Form of TRT Is Better?
Injections and gel are the two most commonly chosen forms of TRT, but they run on completely different logic — one gives a rollercoaster of concentrations and a lower cost, the other stability at the cost of daily discipline and the risk of transferring the hormone to people close to you. We show what that choice actually looks like in practice.
4.7TRT (Testosterone Replacement Therapy) — What Is It and Who Is It For?
TRT isn't a supplement for fatigue — it's pharmacological treatment for a confirmed testosterone deficiency, with a real but limited list of benefits and an equally real list of people who simply don't qualify for it.
4.7How Often to Test Testosterone on TRT? Monitoring Schedule and Checkups
Starting testosterone therapy isn't the end of diagnostics — it's the start of a new, recurring rhythm of checkups. We explain which tests happen at month 3, which at year one, and which need repeating for as long as therapy continues — and how the schedule differs between injectable and gel forms.
4.5TRT and Sleep Apnea — Can You Use Testosterone With Sleep Apnea?
Severe, untreated sleep apnea is often described as a "contraindication" to testosterone therapy — but it isn't an absolute ban. We explain what the Endocrine Society guidelines actually say, why the relationship between testosterone and sleep apnea runs in both directions, and what safe TRT qualification looks like in practice for men with diagnosed or suspected OSA.
4.7TRT — Side Effects and Therapy Monitoring
Erythrocytosis, fertility impact, PSA screening, and the cardiovascular risk question — what testosterone replacement therapy safety actually involves and how it's monitored.
4.7What Tests Are Needed Before TRT? The Complete Pre-Treatment Testing List
Before a physician can qualify a patient for testosterone therapy, a far broader panel of tests is needed than testosterone level alone. The full list of blood tests, symptom questionnaires, and criteria that determine whether TRT is safe and appropriate.
Related articles
PoradnikiHow Long Does TRT Last? Is Testosterone Therapy for Life?
For most men with confirmed primary hypogonadism, TRT is a lifelong therapy — but in some with functional hypogonadism, it's possible to fix the underlying cause and return to natural production. We explain what this depends on, and what living on TRT for years actually means.
August 15, 2026
PoradnikiNormal Testosterone, But You Feel Awful — Could You Still Have Hypogonadism?
A testosterone result that comes back "in range" on a lab printout doesn't always mean everything is hormonally fine — but it doesn't automatically mean you have hypogonadism either. We explain four real explanations for this mismatch, ranked by strength of evidence.
August 15, 2026
PoradnikiTRT and Building Muscle Mass — What Can You Actually Expect From Therapy?
TRT genuinely increases muscle mass and strength in men with hypogonadism — but the scale of that effect is far more modest than bodybuilding forums suggest, and without strength training it remains a fraction of its potential.
August 15, 2026
PoradnikiLow Testosterone After 50 — Symptoms, Testing, and Treatment Options
Past fifty, the risk-benefit math on low testosterone looks different than it does at 40 — more coexisting conditions to factor in, more weight given to prostate and cardiac screening, but one topic usually stops being a problem: fertility.
August 15, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.